- Home
- NVS
NVS
Novartis AG
as 05-30-2025 4:00pm EST
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
| Founded: | 1895 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 230.5B | IPO Year: | 1991 |
| Target Price: | $123.67 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 6.38 | EPS Growth: | -13.29 |
| 52 Week Low/High: | $96.06 - $120.92 | Next Earning Date: | 07-17-2025 |
| Revenue: | $53,222,000,000 | Revenue Growth: | 11.50% |
| Revenue Growth (this year): | 7.22% | Revenue Growth (next year): | 1.94% |
Latest Novartis AG News
NVS Breaking Stock News: Dive into NVS Ticker-Specific Updates for Smart Investing
Insider Monkey
4 days ago
What Makes Novartis AG (NVS) a Differentiated Business?
GlobeNewswire
4 days ago
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
MT Newswires
9 days ago
Market Chatter: Court Denies Novartis' Motion to Dismiss Lawsuit Alleging Asthma Drug Caused Autism
Zacks
10 days ago
Are You Looking for a High-Growth Dividend Stock?
Healthcare Dive
12 days ago
Judge shuts down drugmakers’ 340B rebate plans, for now
Zacks
16 days ago
Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?
Zacks
16 days ago
Should Value Investors Buy Novartis (NVS) Stock?
GlobeNewswire
16 days ago
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
Compare NVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVS Novartis AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.